- New patent expands protection for mitazalimab in Europe
- Patent protects composition of matter for mitazalimab until 2038 (including potential supplementary term)
- Mitazalimab IP portfolio now includes 48 granted patents across multiple territories
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Patent Office (EPO) has granted the company a new patent based on EP Patent No. 3323834 covering its lead drug candidate mitazalimab, a CD40 monoclonal antibody currently being evaluated in a Phase 2 study in 1st line metastatic pancreatic cancer.
The patent, titled "Anti-CD40 Antibodies, Uses and Methods", protects composition of matter for mitazalimab and other CD40 monoclonal antibodies until 2038 (including potential supplementary term). The new patent expands protection for mitazalimab in Europe and brings the total number of patents in the mitazalimab intellectual property portfolio to 48 granted patents and 25 pending patents covering multiple territories, including Europe, North America, Asia, and more.
"The protection of our intellectual property is one of the key pillars of our business strategy, providing a strong foundation for our drug development program and our plans to commercialize our assets," said Søren Bregenholt, CEO of Alligator Bioscience. "The granting of this new patent is a significant addition to our overall patent portfolio, providing vital further protection for our lead clinical asset in Europe. It also comes at an excellent timing with mitazalimab making outstanding progress in the clinic and advancing on its route to market."
Mitazalimab is being evaluated in combination with chemotherapy, mFOLFIRINOX, in the OPTIMIZE-1 Phase 2 study in 1st line metastatic pancreatic cancer. The study is progressing and is on track for top-line readout in early Q1 2024.